论文部分内容阅读
为探讨ｂｃｌ－ ２ 和ｐ５３ 蛋白在非小细胞肺癌中表达之间的关系及意义，应用免疫组织化学Ｓ－ Ｐ法对６２ 例非小细胞肺癌组织进行检测。结果发现：⑴ｂｃｌ－ ２ 蛋白阳性２０ 例（３２－２６ ％） ，其中鳞癌１５ 例，腺癌５ 例；ｐ５３ 蛋白阳性４９ 例（７９－０３ ％ ） ，其中鳞癌３４ 例，腺癌１５ 例。两者比较差异非常显著（ Ｐ＜０－０１） 。⑵ｂｃｌ－２ 和ｐ５３ 的表达强度与肺癌的分化程度密切，但两者之间的表达相反；４８ 例随访患者发现ｐ５３ 表达阳性率与生存期有关，而与ｂｃｌ－ ２ 表达则关系不密切。说明对非小细胞肺癌原位检测ｂｃｌ－ ２、ｐ５３ 蛋白有助肺癌的诊断，对评估肺癌病人预后有重要意义
To investigate the relationship between the expression of bcl-2 and p53 protein in non-small cell lung cancer (NSCLC) and its significance, 62 non-small cell lung cancer tissues were detected by immunohistochemical S-P method. The results showed that: (1) There are 20 cases (32-26%) with bcl-2 protein positive, including 15 cases of squamous cell carcinoma and 5 cases of adenocarcinoma; 49 cases of p53 protein positive (79-03%), including 34 cases of squamous cell carcinoma and 15 cases of adenocarcinoma . The difference between the two was significant (P <0-01). The expression of bcl-2 and p53 was closely related to the differentiation degree of lung cancer, but the expression of bcl-2 and p53 was opposite. The positive rate of p53 expression in 48 cases was related to the survival time, but not to the expression of bcl-2. These results indicate that the in situ detection of bcl-2 and p53 protein in non-small cell lung cancer can help diagnose lung cancer and is of great significance in assessing the prognosis of patients with lung cancer